| abstract |
The present invention relates to an anti-CD66c antibody and its cancer therapeutic use, and can specifically induce T-cell activation or a humoral immune response using an antibody that specifically recognizes CD66c. An antibody that recognizes and binds to CD66c, a nucleic acid molecule that encodes said antibody or antigen-binding fragment, a vector and host cell comprising said nucleic acid molecule and a CD66c-related disease of said antibody or antigen-binding fragment, eg, reduction, prevention of solid tumors, It relates to therapeutic or diagnostic applications. |